Journal of Translational Medicine (Jan 2024)

New advances of the androgen receptor in prostate cancer: report from the 1st International Androgen Receptor Symposium

  • Sherif Mehralivand,
  • Christian Thomas,
  • Martin Puhr,
  • Frank Claessens,
  • Arjanneke F. van de Merbel,
  • Anna Dubrovska,
  • Guido Jenster,
  • Christof Bernemann,
  • Ulrich Sommer,
  • Holger H. H. Erb

DOI
https://doi.org/10.1186/s12967-024-04878-5
Journal volume & issue
Vol. 22, no. 1
pp. 1 – 8

Abstract

Read online

Abstract The androgen receptor (AR) is a crucial player in various aspects of male reproduction and has been associated with the development and progression of prostate cancer (PCa). Therefore, the protein is the linchpin of current PCa therapies. Despite great research efforts, the AR signaling pathway has still not been deciphered, and the emergence of resistance is still the biggest problem in PCa treatment. To discuss the latest developments in AR research, the “1st International Androgen Receptor Symposium” offered a forum for the exchange of clinical and scientific innovations around the role of the AR in prostate cancer (PCa) and to stimulate new collaborative interactions among leading scientists from basic, translational, and clinical research. The symposium included three sessions covering preclinical studies, prognostic and diagnostic biomarkers, and ongoing prostate cancer clinical trials. In addition, a panel discussion about the future direction of androgen deprivation therapy and anti-AR therapy in PCa was conducted. Therefore, the newest insights and developments in therapeutic strategies and biomarkers are discussed in this report.

Keywords